# A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden

> **NCT05387616** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Ludwig-Maximilians - University of Munich** · enrollment: 98 (actual)

## Conditions studied

- Follicular Lymphoma

## Interventions

- **DRUG:** Copanlisib
- **DRUG:** Obinutuzumab

## Key facts

- **NCT ID:** NCT05387616
- **Lead sponsor:** Ludwig-Maximilians - University of Munich
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-10-19
- **Primary completion:** 2023-09-16
- **Final completion:** 2026-05-19
- **Target enrollment:** 98 (ACTUAL)
- **Last updated:** 2024-03-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05387616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05387616, "A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05387616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*